Fabrication of promising competitive graphene nanocomposite transducer to determine Prucalopride succinate in pharmaceutical formulation and in spiked human biological fluids.

The development of a newly fabricated ion-selective electrode (ISE) solid-contacted type for the determination of prucalopride succinate represents a significant advancement in analytical chemistry, particularly in the context of green chemistry principles. The optimization process involved numerous trials to ensure the selection of a cation exchanger and ionophore that offer high sensitivity and selectivity for prucalopride succinate. Through these optimization trials, sodium tetrakis was identified as the most suitable cation exchanger, while calix [8] arene demonstrated the highest affinity towards prucalopride succinate as the ionophore.

Comprehensive and Validated Chromatographic Techniques for the Estimation of Lercanidipine Hydrochloride and Atenolol in Bulk and Combined Dosage Form in the Presence of Lercanidipine Degradation Products with LC/MS Characterization.

Two rapid, smart and validated stability indicating HPLC and TLC techniques were developed to determine atenolol (ATE) and lercanidipine HCl (LER) simultaneously in their pharmaceutical formulation. HPLC chromatographic separation was implemented by using Microsorb C18 (250 × 4.6 mm, 5 μm) column, with mobile phase of acetonitrile and 20 mM potassium dihydrogen phosphate buffer pH 3.

Bioanalytical Validated Spectrofluorimetric Method for the Determination of Prucalopride succinate in Human Urine Samples and Its Greenness Evaluation.

An economical & eco-friendly spectrofluorometric method has been developed for the determination of prucalopride succinate (PRU) in human urine on the basis of the drug's native fluorescence. The type of solvent and the wavelengths of excitation and emission have been carefully selected for optimal experimental conditions. In deionized water, the fluorescence intensity was measured at λ emission 362 nm upon excitation at 310 nm.